FDA Adverse Event Injury Summary report: N

CLARITI 1 DAY (SOMOFILCON A)

MDR report key: 19928582 · Received August 7, 2024

Report

Report Number
3009108089-2024-00004
Event Type
Injury
Date Received
August 7, 2024
Date of Event
June 19, 2024
Report Date
August 7, 2024
Manufacturer
COOPERVISION CL KFT
Product Code
MVN
PMA / PMN Number
K130331
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
OH, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

NO PRODUCT HAS BEEN MADE AVAILABLE FOR MANUFACTURER ANALYSIS AND NO LOT NUMBER PROVIDED FOR MANUFACTURER INVESTIGATION. GIVEN THE LACK OF AVAILABLE DEVICE INFORMATION, THE MANUFACTURER IS UNABLE TO COMPLETE FURTHER INVESTIGATIONS AT THIS TIME AND NO ROOT CAUSE CAN BE ESTABLISHED. THE RELATIONSHIP BETWEEN THE COOPERVISION DEVICE AND THE EVENT IS UNCONFIRMED. SHOULD FURTHER INFORMATION BECOME AVAILABLE, THE MANUFACTURER WILL COMPLETE FURTHER INVESTIGATIONS AS APPROPRIATE AND SUBMIT A FOLLOW-UP REPORT AS APPLICABLE.

Description of Event or Problem · 0

THIS INCIDENT WAS REPORTED TO THE MANUFACTURER BY THE TREATING EYE CARE PROFESSIONAL. IT WAS REPORTED THAT THE PATIENT SOUGHT MEDICAL TREATMENT ON (B)(6) 2024, AND WAS DIAGNOSED WITH A MID-PERIPHERAL CORNEAL ULCER WITH INFILTRATE IN THE RIGHT EYE (OD). THE PATIENT WAS TREATED WITH MOXIFLOXACIN AND MAXITROL EYE DROPS, TO BE INSTILLED EVERY SIX HOURS A DAY, AND TWO WEEKS OF LENS DISCONTINUATION. REPORT INDICATES THAT PATIENT HAD A FOLLOW-UP VISIT ON (B)(6) 2024. IT IS REPORTED THAT THE INCIDENT HAS RESOLVED AS OF (B)(6) 2024, WITHOUT PERMANENT INJURY OR VISION IMPACT, HOWEVER, MEDICAL INTERVENTION WAS REQUIRED TO PREVENT PERMANENT IMPAIRMENT OF EYE FUNCTION OR STRUCTURE. SHOULD FURTHER INFORMATION BECOME AVAILABLE, A FOLLOW-UP REPORT WILL BE SUBMITTED AS APPROPRIATE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
220479 CLARITI 1 DAY (SOMOFILCON A) CLARITI 1 DAY (SOMOFILCON A) MVN COOPERVISION CL KFT UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 25 YR Female Required Intervention| O